AGM presentation – 16 November 2023

RAD
RADIOPHARM THERANOSTICS

IMPORTANT NOTICE AND DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation is not a prospectus or other disclosure document under the *Corporations Act 2001* (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

COMPANY VISION & STRATEGY

SUCCESSFULLY FIGHT CANCER THROUGH INNOVATIVE RADIOPHARMACEUTICAL THERAPIES

Unique Business Model

- High resource allocation to R&D
- Low resource allocation to G&A – small team of 11 FTE.
- Expanded partnerships and strategic alliances

Intellectual Property

- Extensive Patient portfolio for targets through 2040

Differentiated Targeting Molecules

- Radiopharm is in a unique space where other radiopharmaceutical companies are not known to be focused
- Proprietary molecules designed to identify and attack a broad range of malignancies

Deep Expertise in Radiopharmaceuticals

- All team members with previous Imaging or Therapeutic radiopharmaceutical experience
- Extensive team of accredited multinational researchers

Timely, Accurate & Rich News Flow Expected in the Next 6-12 Months

- Transitioning four different molecules from pre-clinical to clinical stage

EXPANDED PARTNERSHIPS & STRATEGIC ALLIANCES

- UNIQUE BUSINESS MODEL: LOW CAPITAL INTENSITY, FLEXIBLE RESOURCE ALLOCATION



TRANSITION FROM PRECLINICAL TO CLINCAL STAGE COMPANY IN ONLY TWO YEARS



PORTFOLIO PRIORITIES – Two Imaging & Two Therapeutics

RAD CODE	MOLECULE & TARGET	INDICATION	ISOTOPE	PRECLINICAL	PHASE I	PHASE IIA	PHASE IIB	PHASE III	NOTES
				IMAGING					
RAD101	Pivalate (Fatty Acid Synthetase)	BRAIN METS	F18						Phase 2b first patient expected in Q4 IND approval after USA Tech transfer completion in Q4
RAD301	Trivehexin ($\alpha V\beta 6$ Integrin)	PANCREATIC	Ga68						ODD received May 2023 FDA IND received 9 patient Ph 1 trial: first patient expected in November, last patient by Dec 2023
				THERAPEUTIC					
RAD204	Sd mAb (PD-L1)	NSCLC	Lu177						Australian Ethics approval received 10/2023. First patient in Q4
RAD 202	Sd mAb (HER 2)	BREAST GASTRIC	Lu177						FDA IND submission in Q4, first patient in Q1 2024

RAD 101 Imaging: F18-PIVALATE





F18-PIVALATE

Selectively targets fatty acid synthetase which is overexpressed in tumours but not normal brain cells

BRAND VISION:

BECOME THE LEADING PET AGENT FOR IMAGING BRAIN METASTASIS

- 300,000 new patients every year in USA only
- MRI current standard of care, but has limitations in patient post surgery or post stereotactic radiation surgery (pseudo-progression)

RAD 101 Imaging: F18-PIVALATE

CLINICAL DEVELOPMENT & REGULATORY STRATEGY

- Ongoing Tech transfer from UK to USA. IND approval after Tech transfer finalized
- 21 months to complete late-stage development (Phase IIb + Phase III)
- ~30 months to anticipated NDA Approval and first commercial sales
- USD 364m peak yearly sales potential (Jones Group independent report)
- Only 1 expected competitor: Axumin (Bracco) currently in Phase III

PRECLINICAL	PHASE I	PHASE IIa	PHASE 2b	PHASE 3	APPROVAL & COMMERCIAL LAUNCH
					
	24 pts	17 pts	30 pts	150 pts	
√	√	√	Q4 – Q2 2024	Q3 2024 – Q2 2025	1H 2026

RAD 301 Imaging: Ga68-TRIVEHEXIN





TRIVEHEXIN

RGD peptide (arginylglycylaspartic acid)

Integrin αvβ6 receptor antagonist

- Marker for tumour invasion and metastatic growth
- Expression correlates with decreased survival in numerous carcinomas

BRAND VISION: FIRST TO MARKET PET AGENT FOR IMAGING PANCREATIC CANCER

- High unmet need in detecting and monitoring pancreatic cancer
- Current standard of care (FDG & MRI) have significant limitations
- FDA IND approval received ; Orphan drug Designation granted (5/2023)
- Multi-indication potential beyond PDAC (Head & Neck, NSCLC, TNBC, Colorectal)

RAD 301 Imaging: Ga68-TRIVEHEXIN

CLINICAL DEVELOPMENT & REGULATORY STRATEGY

- 66 patients already dosed under compassionate use (solid safety profile)
- 33 patients dosed under Pilot Study (presented at EANM 9/2023)
- IND approved Phase I start imminent, followed by registrational trial (leveraging RWE data)
- USD 240m peak yearly sales potential in PDAC only (Bell Potter independent report)
- Only 1 expected competitor: Integrin αvβ6 - αvβ1 (UC Davis) currently in Phase I

COMPASSIONATE USE (Germany)	Pilot study in PDAC + H&N	PHASE I	PHASE II	PHASE III	APPROVAL & COMMERCIAL LAUNCH
66 pts	33pts	9 pts	30 pts		
√	√	Fully recruited by Dec 2023	Apr 2024 – April 2025		1H 2026

RAD 204 Therapeutic: NANOMAB PD-L1





PD-L1 NANOMAB

Single domain monoclonal antibody (Sd mAb)

PD-L1 Immune Checkpoint Protein

- Overexpression mediates evasion of immune responses by cancer cells
- Blockade by antibodies leads to tumour regression

BRAND VISION:

FIRST TO MARKET CHECKPOINT INHIBITOR-RADIOPHARMACEUTICAL COMBINATION

- Lead Indication : non-small cell lung cancer
- 200,000 new patients every year in USA only
- ~70% patients refractory to Check Point Inhibitors regimen

RAD 204 Therapeutic: NANOMAB PD-L1

CLINICAL DEVELOPMENT & REGULATORY STRATEGY

- Human pharmacokinetic and Biodistribution proven with Imaging agent (positive Phase I in 16pts in 2019
- Strategic Collaboration with Lantheus for the PDL-1 Imaging agent
- Phase I therapeutic dose escalation in Australia (approval to start received in October)
- Phase II combo therapy trial with checkpoint inhibitor
- Blockbuster sales potential (Company assessment ongoing)
- No other PDL1 radiopharmaceuticals in preclinical or clinical development

PRECLINICAL	Imaging PHASE I	Therapeutic PHASE I	PHASE II
	16pts	27 pts	50 pts
√	√	Q4 2023– Q1 2025	Q3 2025 – Q3 2027

RAD 202 Therapeutic: NANOMAB HER-2



HER 2 NANOMAB

Single domain monoclonal antibody (Sd mAb)

HER 2 pathway proven in Oncology

Overexpression in Breast Cancer and Gastroesophageal cancers

BRAND VISION:

BREAST & GASTRIC HER2+ THERAPY FOR PATIENTS REFRACTORY to TRASTUZUMAB / DERUXTECAN

- 47,000 new patients every year in USA only
- Suboptimal toxicity profile ADCs (2nd line metastatic cancer) opens opportunity for new agents

RAD 202 Therapeutic: NANOMAB HER-2

CLINICAL DEVELOPMENT & REGULATORY STRATEGY

- Human pharmacokinetic and Biodistribution proven with Imaging agent (positive Phase I in 10pts in 2021, follow by IIT in Germany in additional 6 pts.
- Phase I therapeutic dose escalation in USA (approval to start expected in Q4) in Breast / Gastric Cancers
- Phase II therapy trial in the Breast or Gastric (depending on Phase I data)
- Blockbuster sales potential (Company assessment ongoing)
- Only 1 competitor (Precirix – private company) currently in Phase I

PRECLINICAL	Imaging PHASE I	Therapeutic IND Approval	PHASE I	PHASE II
	10pts + IIT in 6pts		21 pts	50 pts
√	√	Q4 2023	Q1 2024 – Q3 2025	Q4 2025 – Q4 2027

TRANSITION FROM PRECLINICAL TO CLINICAL STAGE COMPANY WITH 4 MOLECULES

- 2 READ OUTS BY MID 2024 -

RAD CODE	MOLECULE & TARGET	INDICATION	ISOTOPE
RAD101	Pivalate (Fatty Acid Synthetase)	BRAIN METS	F18
RAD301	Trivehexin ($\alpha V\beta 6$ Integrin)	PANCREATIC	Ga68
RAD204	Sd mAb (PD-L1)	NSCLC	Lu177
RAD 202	Sd mAb (HER 2)	BREAST GASTRIC	Lu177



INFLECTION POINTS

CONTACT US

Riccardo Canevari

CEO & MANAGING DIRECTOR

Radiopharm Theranostics Limited
T +1 862 309 0293

E rc@radiopharmtheranostic.com

W www.radiopharmtheranostics.com

Paul Hopper

Executive Chairman

Radiopharm Theranostics Limited
T +61 406 671 515

E paulhopper@lifescienceportfolio.com

W www.radiopharmtheranostics.com